PMID- 37389200
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230703
IS  - 1939-4551 (Print)
IS  - 1939-4551 (Electronic)
IS  - 1939-4551 (Linking)
VI  - 16
IP  - 6
DP  - 2023 Jun
TI  - Vernal keratoconjunctivitis: Current immunological and clinical evidence and the 
      potential role of omalizumab.
PG  - 100788
LID - 10.1016/j.waojou.2023.100788 [doi]
LID - 100788
AB  - Vernal keratoconjunctivitis (VKC) is a severe ocular allergic disease 
      characterized by chronic inflammation of the cornea and conjunctiva that may lead 
      to loss of visual acuity and blindness. The disease occurs primarily in children 
      and is more common in geographical regions characterized by warm temperatures and 
      high humidity. The clinical manifestations of VKC, when inadequately treated, may 
      lead to severe complications and corneal damage. The prevalence of allergen 
      sensitization, specific serum immunoglobulin E (IgE), and specific tear IgE was 
      reported in approximately 55%-60% of patients with VKC, confirming the 
      involvement of IgE-mediated and non-IgE-mediated mechanisms in the 
      pathophysiology of the condition. This article explores current knowledge on the 
      immunological pathways of VKC and the role of the monoclonal anti-IgE antibody, 
      omalizumab, in its management. The review evaluated the effects of omalizumab 
      beyond the direct IgE-mediated reactions and discusses its potential as a 
      therapeutic target for VKC. Multiple retrospective analyses, case series, and 
      case reports have reported the effectiveness of omalizumab in the management of 
      VKC. A summary of the clinical data from these studies revealed that in children 
      with VKC omalizumab treatment was well tolerated with improvement or resolution 
      of ocular symptoms, reduction in steroid use, and enhancement of quality of life. 
      Omalizumab may serve as a promising treatment option for VKC due to its ability 
      to target both IgE-mediated and non-IgE-mediated pathophysiological pathways. 
      Larger, controlled clinical trials are needed to support these findings.
CI  - (c) 2023 The Authors.
FAU - Doan, Serge
AU  - Doan S
AD  - Ophthalmology Department of Fondation A de Rothschild and Hopital Bichat, 25-29 
      Rue Manin, 75019, Paris, France.
FAU - Papadopoulos, Nikolaos G
AU  - Papadopoulos NG
AD  - Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.
AD  - Division of Infection, Immunity and Respiratory Medicine, University of 
      Manchester, Manchester, UK.
FAU - Lee, Jason K
AU  - Lee JK
AD  - Evidence Based Medical Educator Inc., Toronto Allergy and Asthma Clinic, Toronto, 
      Ontario, Canada.
FAU - Leonardi, Salvatore
AU  - Leonardi S
AD  - Pediatric Respiratory Unit, AOUP "G. Rodolico-San Marco", University of Catania, 
      Catania, Italy.
FAU - Manti, Sara
AU  - Manti S
AD  - Pediatric Respiratory Unit, AOUP "G. Rodolico-San Marco", University of Catania, 
      Catania, Italy.
AD  - Pediatric Unit, Department of Human Pathology of the Adult and Developmental Age 
      "Gaetano Barresi", University of Messina, Messina, Italy.
FAU - Lau, Susanne
AU  - Lau S
AD  - Department of Pediatrics, Division of Respiratory Medicine, Immunology and 
      Critical Care Medicine, Charite Universitatsmedizin Berlin, Berlin, Germany.
FAU - Rondon, Carmen
AU  - Rondon C
AD  - Allergy Research Group, Instituto de Investigacion Biomedica de Malaga 
      (IBIMA)-Plataforma BIONAND.RICORS "Inflammatory Diseases", ARADyAL, Malaga, 
      Spain.
AD  - Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.
FAU - Sharma, Vibha
AU  - Sharma V
AD  - Lydia Becker Institute of Immunology and Inflammation, University of Manchester, 
      Manchester, UK.
FAU - Pleyer, Uwe
AU  - Pleyer U
AD  - Department of Ophthalmology, CVK, Charite Universitatsmedizin, Berlin, Germany.
FAU - Jaumont, Xavier
AU  - Jaumont X
AD  - Novartis Pharma AG, Basel, Switzerland.
FAU - Lazarewicz, Slawomir B
AU  - Lazarewicz SB
AD  - Novartis Pharma AG, Basel, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230615
PL  - United States
TA  - World Allergy Organ J
JT  - The World Allergy Organization journal
JID - 101481283
PMC - PMC10300397
OTO - NOTNLM
OT  - Allergy
OT  - Biologics
OT  - IgE
OT  - Omalizumab
OT  - Vernal keratoconjunctivitis
EDAT- 2023/06/30 13:11
MHDA- 2023/06/30 13:12
PMCR- 2023/06/15
CRDT- 2023/06/30 10:14
PHST- 2023/01/06 00:00 [received]
PHST- 2023/05/08 00:00 [revised]
PHST- 2023/05/21 00:00 [accepted]
PHST- 2023/06/30 13:12 [medline]
PHST- 2023/06/30 13:11 [pubmed]
PHST- 2023/06/30 10:14 [entrez]
PHST- 2023/06/15 00:00 [pmc-release]
AID - S1939-4551(23)00048-0 [pii]
AID - 100788 [pii]
AID - 10.1016/j.waojou.2023.100788 [doi]
PST - epublish
SO  - World Allergy Organ J. 2023 Jun 15;16(6):100788. doi: 
      10.1016/j.waojou.2023.100788. eCollection 2023 Jun.